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A B S T R A C T
Purpose: To analyze the electroclinical features, neuroimaging ﬁndings, treatment, and outcome of 12
patients with febrile infection-related epilepsy syndrome (FIRES).
Methods: This is a retrospective study of 12 children with FIRES with a mean time of follow-up of 6.5
years carried out at the Garrahan Hospital of Buenos Aires between 1997 and 2012.
Results: Eight males and four females had focal status epilepticus preceded by febrile infection with a
mean age at presentation of 8.5 years. In the acute period, the treatment included antiepileptic drugs
(AEDs) in all cases, immunotherapy in 10 cases, and burst-suppression coma in eight. The ketogenic diet
was tried in two, plasmapheresis in one, and rituximab in one. Two patients treated with IVIG and one
patient given steroids had a good response, but in this phase only three patients had a prolonged good
response to IVIG and a ketogenic diet. No patients died in this period. In the chronic epilepsy phase, all
children had seizures arising from neocortical regions. All patients had refractory epilepsy, and most
mental retardation, and behavioral disturbances. All received different AEDs and in this phase a third
patient was put on a ketogenic diet. One patient was operated without good results. Only two cases had a
good outcome after 2 and 10 years of follow-up.
Conclusion: FIRES is a well-deﬁned severe epileptic syndrome, probably in the group of epileptic
encephalopathies, characterized by focal or multifocal seizures arising from the neocortical regions with
an unknown etiology. Immunoglobulin and the ketogenic diet may be considered a potentially
efﬁcacious treatment.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Febrile infection-related epilepsy syndrome (FIRES) is consid-
ered a severe epileptic encephalopathy with multifocal refractory
status epilepticus.1
In 1986 Awaya and Fukuyama ﬁrst described an encephalitis-
like entity occurring in previously normal children.2 Since then,
the syndrome has been variably called severe refractory status
epilepticus due to presumed encephalitis,3 idiopathic catastrophic
epileptic encephalopathy,4 new-onset refractory status epilepticus,5
devastating epileptic encephalopathy in school-aged children,1
acute encephalitis with refractory repetitive partial seizures,6 febrile
infection-related epilepsy syndrome,7 and fever-induced refractory
epileptic encephalopathy in school-age children.8
FIRES in previously healthy children is characterized by three
phases: An initial phase with a simple febrile infection, a few days* Corresponding author at: Neurology Department, Juan P Garrahan Pediatric
Hospital, Combate de los Pozos 1881, Buenos Aires CP 1245, Argentina.
Tel.: +54 11 4824 0299; fax: +54 11 4843 6116.
E-mail address: rhcaraballo@arnet.com.ar (R.H. Caraballo).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.04.005later followed by an acute phase with highly recurrent focal
seizures that evolve rapidly into refractory status epilepticus often
with no more fever and generally without additional neurological
features, and ﬁnally a chronic phase consisting of drug-resistant
epilepsy and neuropsychological impairment.7 These symptoms
occur mostly in children between 3 and 15 years of age, but adult
patients have also been described.
Series of patients with this particular epileptic encephalopathy
have been published in Japan, the UK, France, Germany, Italy, the
US, Austria, Singapore, and Taiwan.1,4–10
The etiology and the mechanisms underlying of FIRES are still
unknown, and an immunologic source,7,10–14 a genetic predispo-
sition, and an inﬂammation-mediated process11 have been
hypothesized. Currently, the ketogenic diet may be considered
as an efﬁcacious treatment.8
Here, we analyze the electroclinical features, neuroimaging
ﬁndings, treatment, and outcome of 12 patients with FIRES.
2. Methods
This is a retrospective study conducted at the Garrahan Hospital
of Buenos Aires of 12 children with FIRES seen between 1997 andvier Ltd. All rights reserved.
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of follow-up of 6.5 years (range, 1–15 years).
The inclusion criteria were the following: Previously healthy
children between 2 and 16 years of age with normal psychomo-
tor development, acute onset of refractory seizures associated
with an encephalitis-like illness; no infectious pathogen found
on testing of cerebrospinal ﬂuid (CSF), serum, or other body
ﬂuids; and evolution to chronic epilepsy without an anticonvul-
sant-free latent period.8 The status was considered refractory if it
failed to respond to initial antiepilepic drug treatment (intrave-
nous benzodiazepines, phenytoin, phenobarbital, as well as
valproic acid and levetiracetam).
Patients with a similar presentation due to viral encephalitis,
acute disseminated encephalomyelitis, Rasmussen encephalitis,
structural brain abnormalities, or metabolic disorders were
excluded.
Based on the medical records we evaluated personal ante-
cedents, family history, and clinical details including seizure
semiology and management in the acute period. Virological,
immunological, metabolic, and genetic investigations were stud-
ied. Neuropsychological assessments as well as clinical features
and management of the chronic epilepsy were also analyzed.
All patients had CSF, blood, and other body ﬂuids tested for
infective pathogens. In all cases markers of inﬂammation in CSF
and blood were investigated. Different antibody and metabolic
tests were performed. Genetic testing and brain biopsy were not
performed in any of the patients.
All interictal and ictal EEG recordings, computerized tomog-
raphy (CT) scans, and magnetic resonance imaging (MRI)
performed in both the acute and chronic phases were analyzed.
Six and four patients had video-EEG recordings in the acute and
chronic phases, respectively. All patients underwent MRI study at
1.5 T in the acute period and in the chronic phase, and three of
them at 3 T with an epilepsy protocol in the chronic period.
Positron emission tomography scans were not done in any of the
patients in either acute or chronic phases.
In the chronic phase, we analyzed the electroclinical features,
treatment, and evolution. Behavior was assessed by parentalFig. 1. Ictal EEG recording shows rhythmic theta activities predominantly in report. The neuropsychological evaluation included standardized
tests of intellectual abilities in all patients.
3. Results
3.1. General features
We included 12 patients, eight males and four females. All were
previously well, with a normal development. No patients had
remarkable personal antecedents or a past history of seizures. One
patient had a family history of febrile seizures and another had a
family history of epilepsy.
3.2. Clinical and EEG presentation
The children had a mean and median age at presentation of 8.5
and 10 years (range, 2–13.5 years), respectively. Upper respiratory
tract infection and gastroenteritis, both associated with fever, were
observed in nine and three patients, respectively. Clinical
encephalitis-like features characterized by fever, headache,
drowsiness, and confusion preceded the onset of seizures by 2–
10 days.
In the acute phase, the seizures were focal with loss of
consciousness in all children, and with secondary generalization
characterized by bilateral clonic seizures in three. Autonomic
manifestations, such as pallor, apnea, and cyanosis, were
registered in eight patients. Three patients also had apparently
generalized seizures. The seizures rapidly increased in frequency
(28–102 seizures daily) and exacerbated into status epilepticus
within 24–36 h. One patient had repetitive facial myoclonias.
The duration of intensive care treatment was 2–40 days (median
16 days).
Interictal EEG recordings showed diffuse delta–theta back-
ground slowing was seen in all cases. The initial ictal EEG
recordings showed a temporal seizure onset in four children (33%),
frontotemporal in four (33%), frontal in two (16.5%), and
frontoparietal in two children (16.5%) (Fig. 1). All of them rapidly
developed multifocal and independent seizures, unilateral orthe right frontal lobe associated with left focal orofacial clonic seizures.
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the contralateral hemisphere in nine involving different lobes.
3.3. Investigations
All the patients underwent CSF study and pleocytosis was found
in seven (58.2%). CSF protein was elevated in one patient. Anti-
NMDARantibodies were negative in two patients, and detection of
oligoclonal bands in CSF was performed in six patients. All
evaluations were negative, except that oligoclonal bands in CSF
were found in two of six patients.
Magnetic resonance imaging (MRI) was performed in all cases.
The initial MRI was normal in ﬁve patients of 12. The
abnormalities found in the remaining seven patients were
signal hyperintensities in both hippocampi in ﬁve patients
(Fig. 2A). In three of them, the periinsular region was also
affected. Hyperintensity in the basal ganglia was detected in one
case (Fig. 2C). The follow-up MRI revealed generalized atrophy in
four (Fig. 2B) and signal hyperintensity in four other patients. The
signal hyperintensity was located in both hippocampi in three
and in the periinsular region in one.
3.4. Treatment
All patients were treated with acyclovir and/or antibiotics to
cover the possibility of central nervous system infections for twoFig. 2. (A) FLAIR sequence brain MRI in the acute period shows bilateral. hyperintensity in
and subcortical atrophy with ventricular enlargement. (C) FLAIR sequence brain MRI in th
nuclei in another patient.weeks or until positive results were ruled out. All patients received
multiple antiepileptic schemes, including phenobarbital (12),
phenytoin (12), benzodiazepines (12), levetiracetam (12), sodium
valproate (6), thiopentone (6), carbamazepine (5), oxcarbazepine
(4), and topiramate (6) with a negative response. Eight patients
were treated with barbiturates at doses sufﬁcient to induce burst-
suppression on the EEG. Five of them responded well temporarily.
Thus, barbiturates were effective in stopping the status epilepticus
in these ﬁve patients.
Ten patients received three times 1.2 g intravenous immuno-
globulin (IVIG) every 10 and 14 days, except three cases who
received IVIG every 21 days over 4, 6, and 8 months, respectively,
and nine patients received steroids in different forms and doses.
Most of them received a pulse of methyl prednisolone at 30 mg/
kg/day over 5 days followed by oral prednisone at 1 mg/kg/day.
Two patients treated with IVIG and one patient given steroids had
a good response, but the response was sustained in only one
treated with IVIG with 50% seizure reduction.
Two patients were treated with a ketogenic diet in the acute
phase, of whom one showed a good and sustained response with
a 50–75% seizure reduction. The remaining patient had a seizure
reduction of less than 50%. One patient did not respond well to
plasmapheresis. One patient had a partial response (a seizure
reduction of approximately 50%) to two doses of rituximab,
however, the treatment was withdrawn due to marked lym-
phopenia. both hippocampi. (B) 18 months later. FLAIR sequence brain MRI evidences cortical
e acute phase shows bilateral and symmetric involvement of caudate and lentiform
Fig. 3. The same patient as in Fig. 1, 15 months later. The ictal EEG recording shows rhythmic theta–delta activities propagatedin the right hemisphere arising from the right
frontal lobe associated with similar clinical manifestations as in Fig. 1.
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All patients had epilepsy and there was no prolonged period of
time without seizures between the acute and the chronic phase.
Two patients became seizure free after 18 and 25 months of
antiepileptic treatment, respectively. The other 10 patients have
refractory epilepsy. All patients had simple or complex focal
seizures. Seizure semiology, based on parents’ report in all patients
and video-EEG recording in four patients, revealed head-and-eye-
version episodes in four cases, unilateral tonic and clonic seizures
in two, and unilateral orofacial clonic seizures in one. Dystonic
posturing was observed in two patients and autonomic manifesta-
tions in two other cases. Behavioral arrest and loss of conscious-
ness associated with automatisms occurred in seven patients,
three of whom had an abdominal aura. Four of 12 patients had
secondary generalized tonic or tonic–clonic seizures. In two
patients the seizures had a multifocal origin. Focal status
epilepticus occurred in three patients requiring admissions to
the intensive care unit. The seizures occurred daily in two cases,
weekly in one patient, monthly in four, and every 2–4 months in
the remaining patients. The seizures occurred in clusters in ﬁve
patients. All patients had seizures while awake and four of them
also during sleep.
Ten patients currently receive two to three AEDs. Two of 12
patients are seizure free after 2 and 10 years of follow-up. Two
patients continue on a ketogenic diet. They have brief seizures
every 2 and every 4 months, respectively. Three patients continue
receiving IVIG without good results. Surgery was performed in one
patient with refractory temporal lobe epilepsy secondary to mesial
sclerosis; she has a 50% seizure reduction after 2 years of follow-
up. In one patient with refractory seizures and frequent episodes of
status epilepticus, a vagus nerve stimulator has recently been
implanted.
The background interictal EEG recordings showed slow-wave
activity in all patients. Bilateral and focal slow waves mainly in
frontotemporal regions were also observed in ten of 12 patients. All
patients had focal spikes predominantly in temporal, frontal, andfrontotemporal lobes. Sharp waves and spike waves were
registered in ﬁve and three patients, respectively. Bilateral and
synchronous discharges were recorded in two patients. General-
ized paroxysms and focal or generalized fast rhythms were not
registered. EEG abnormalities were activated during sleep in ﬁve
patients. No changes were observed during the hyperventilation.
The ictal EEG showed rhythmic theta–delta followed by fast
rhythms in six cases. Ictal discharges were characterized by
rhythmic theta–delta activities followed by rhythmic spikes and
spike-wave discharges in four cases (Fig. 3). Fast activity followed
by slow activity that increased in voltage and frequency was seen
in two other cases. The ictal EEG manifestations were focal in six,
multifocal unilateral in three, and multifocal and bilateral in the
remaining three patients.
During the chronic epilepsy period the MRI showed mild diffuse
cortical atrophy in three patients and severe diffuse cortical
atrophy in two. Two patients had unilateral mesial temporal
sclerosis and two had bilateral mesial temporal sclerosis.
In Table 1, the electroclinical features, investigations, imaging
ﬁndings, treatment, and outcome of the patients in our series are
shown.
4. Discussion
Our series of patients supports that FIRES is a severe epileptic
encephalopathy subsequent to a febrile event. To our knowledge,
these are the ﬁrst patients with this particular epileptic syndrome
described in South America. The age at onset of the syndrome was
in pre-school or school years. The clinical manifestations of the
children in this study are very similar to those of other series of
patients recently published.5,6,8,12
In our patients as in the other series, barbiturates at high doses
to induce burst-suppression coma were the main effective
treatment to temporarily stop the seizures in the acute phase.12
Despite their secondary risks, they may be considered the best
option to end the seizures in the acute period.8 Two of our cases
responded well to a ketogenic diet in the acute phase of FIRES
Table 1
The electroclinical features, investigations, imaging ﬁndings, treatment, and outcome of 12 patients with FIRES.
Patients Epilepsy
(age at
onset,
years)
Type of
seizure
(AP)
Interictal
EEG (AP)
Ictal EEG
origin (AP)
Brain MRI (AP) Investigations Treatment (AP) Therapeutic
response
(AP)
Type of seizure
(CEP)
Interictal EEG
(CEP)
Ictal EEG (CEP) MRI ﬁndings
(CEP)
Treatment
(CEP)
Outcome
1 2 FMS, SE DSW, MS Fronto
parietal
Normal (–) CSF study:
pleocytosisa
BDZ, PHT, LVT,
BSC, IT
Temporary Focal clonic
seizures, SGTCS
Bilateral frontal
spikes and
sharp waves
Frontoparietal
(theta–delta and
fast rhythms)
Brain atrophy AEDs, IVIG RE, MR
2 4 FMS, CFS SE DSW, FS Temporal Normal (–) CSF study:
pleocytosisa
BDZ, PHT, LVT,
BSC, IT
Temporary Head and eye
deviation, FCS
Frontotemporal
spikes and spike
waves
Temporal
(theta–delta
and spike-
wave
discharges)
Brain
atrophy
AEDs
RE,
MR,
BD
3 6 FMS, AGS SE DSW, MS Temporal Hippocampus
signal
hyperintensity
(–) CFS study:
oligoclonal
bandsa
BDZ, PHT, VPA,
BSC, IT
Temporary Head and eye
deviation
Temporal
spikes and
sharp waves
Temporal (theta–
delta and fast
rhythms)
MTS AEDs,
surgery
RE, MR, BD
4 13.5 FMS, FCS, SE DSW, MS,
BP
Fronto
temporal
Hippocampus
and periinsular
signal
hyperintensity
(–) CSF study:
pleocytosisa
BDZ, PHT, LVT,
VPA, BSC, IT,
plasm
Negative Focal clonic
seizures, FCS
Temporal
spikes and
spike waves
Fronto temporal
(fast and theta–
delta rhythms)
MTS AEDs, VNS RE, MR, BD
5 9 FCS, SGTCS,
SE
DSW, MS,
BP
Frontal Basal ganglia
hyperintensity
(–)a BDZ, PHT, LVT,
VAP, BSC, IT
Negative FCS, SGTCS Frontal spikes Frontal (theta–
delta and fast
rhythms)
Normal AEDs RE, MR, BD
6 12 Focal dystonic
seizures,
AM, SE
DSW, MS Frontal Normal (–) CFS study:
oligoclonal
bandsa
BDZ, PHT, PHB,
LVT, IT, KD
Temporary Focal dystonic
seizures, AM
Bilateral fronto
temporal
spikes
Frontal (theta–
delta and fast
rhythms)
Normal AEDs, KD Sporadic
seizures,
MR, BD
7 6 FCS, AM, SE DSW, MS Temporal Hippocampus
signal
hyperintensity
(–) CSF study:
pleocytosisa
BDZ, PHT, PHB,
LVT, IT
Good FCS, AM Frontal spikes Temporal (theta–
delta and spike
wave discharges)
Normal AEDs Normal,
mild BD
8 10.5 Focal tonic
seizures,
SGTCS, SE
DSW, MS Fronto
temporal
Normal (–)a MDZ, PHT, IT Good Focal tonic
seizures, SGTCS
Temporal
spikes and
sharp waves
Frontotemporal
(theta–delta and
fast rhythms)
Brain atrophy AEDs Normal, BD,
dyslexia
9 9.5 FCS, FMS,
AGS, SE
DSW, MS,
BP
Fronto
temporal
Hippocampus
and periinsular
signal
hyperintensity
(–) CSF study:
pleocytosisa
BDZ, PHT, LVT,
BSC, KD
Temporary FCS, SGTCS Temporal
spikes
Frontotemporal
(theta–delta and
spike-wave
discharges)
MTS AEDs, IVIG RE, MR, BD
10 8.5 FCS, FMS, SE DSW, BS,
MS
Temporal Hippocampus
signal
hyperintensity
(–) CSF study:
pleocytosisa
MDZ, PHT, IT Temporary FCS, head and
eye version
Frontal spikes
and sharp
waves
Temporal (theta–
delta and spike-
wave discharges)
MTS AEDs, KD RE, MR, BD
11 12.5 FCS, focal
dystonic
seizures,
AGS, SE
DSW, MS,
PLED
Fronto
parietal
Normal (–)a BDZ, PHT, LVT,
VPA, BSC, IT,
rituximab
Negative FCS, focal
dystonic
seizures
Frontal spikes
and spike
waves
Frontoparietal (fast
and theta–delta
rhythms)
Brain atrophy AEDs, IVIG RE, MR, BD
12 11.5 FMS, FCS, SE DSW, MS Fronto
temporal
Hippocampus
and periinsular
signal
hyperintensity
(–) CSF study:
pleocytosisa
BDZ, PHT, LVT,
BSC
Negative Head and eye
version
Frontal spikes
and sharp
waves
Frontotemporal
(fast and theta–
delta rhythms)
Brain atrophy AEDs, KD Sporadic
seizures,
MR, BD
Abbreviations: AP, acute period; BDZ, benzodiazepines; CEP, chronic epilepsy phase; FMS, focal motor seizures; FCS, focal complex seizures; AM, autonomic manifestations; AGS, apparently generalized seizures; SE, status
epilepticus; DSW, diffuse slowwaves; BS, burst suppression; PLED, periodic lateralizing epileptic discharges; MS, multifocal spikes; FS, focal spikes; BP, bilateral paroxysms; BSC, burst-suppression coma; IT, immunotherapy; MDZ,
midazolam; PHT, phenytoin; plasmplasmapheresis; SGTCS, secondary generalized tonic–clonic seizures; MTS, mesial temporal sclerosis; KD, ketogenic diet; IVIG, intravenous immunoglobulin; RE, refractory epilepsy; MR, mental
retardation; PHB, phenobarbital; BD, behavioral disturbances.
a Infectious agents, metabolic, and immunologic studies.
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Another patient responded well to IVIG, as did two patients with
FIRES published by Specchio et al.14 One patient in our series
received rituximab with a partial response, however, the drug had
to be withdrawn due to adverse events. The ﬁrst experience with
rituximab was reported by Howell et al.12 without good results.
The same group was also the ﬁrst to use vagus nerve stimulation
for the treatment of patients with FIRES in the acute phase.12 Many
other patients were treated with various agents in the acute phase,
including propofol, lidocaine, ketamine, verapamil, and plasma-
pheresis, with no positive response.8 Nevertheless, immunothera-
pies, including plasma exchange, are reported to be of beneﬁt not
only in the acute but also in the chronic phase in rare cases.8,12,14
Considering the development into chronic epilepsy, it is
interesting to analyze the electroclinical features, treatment,
and evolution of patients with FIRES. One question is whether to
divide the syndrome into two phases (acute and chronic) or
whether to consider it as a single process that starts with a
dramatic electroclinical event that in most of the patients
continues with seizures without a silent period. None of our
cases had a seizure-free period, similar to other series of patients
published.12 Moreover, the fact that the seizures have the same
electroclinical features in both periods supports the hypothesis
that FIRES consists of a single pathological event. The electro-
clinical ﬁndings of our series of patients as well as those of other
patients published are very similar, suggesting a well-deﬁned
epileptic syndrome. It is characterized by refractory simple or
focal seizures very often without secondary generalization.
Autonomic seizures are frequent. The ictal EEGs show that the
seizures are focal or multifocal arising independently from one or
both hemispheres with similar electroencephalographic features.
The facial and limb focal motor manifestations and the ictal EEG
ﬁndings suggest that they may have a neocortical frontal lobe
origin.6,9,13
Mesial temporal sclerosis was considered the cause of the
refractoriness of the seizures of these patients with FIRES.1
However, our case with refractory seizures and mesial temporal
sclerosis who underwent surgery continued with seizures,
and thus we believe that the epileptogenic zone may also
involve the periinsular or other frontal lobe regions. To our
knowledge, ours is the ﬁrst patient with FIRES who received
surgical treatment.
In the chronic phase, no AEDs were reported as beneﬁcial in the
treatment of patients with FIRES, despite different schemes. Other
therapeutic alternatives may be considered, such as steroids, IVIG,
the ketogenic diet, vagus nerve stimulation, and surgery.1,6,9,13–15
In our present series of patients, two cases had a good
outcome. Similar exceptional cases have been published by
Kramer et al.9 Therefore, we may consider that the course of the
disease is severe most patients, but that some patients may have
a relatively better outcome. These patients could suggest that
the clinical spectrum of FIRES may be broader.
FIRES is considered to have an immune-mediated or
inﬂammatory basis, taking into account the absence of an
infective cause. However, patients with a similar course
associated with infectious agents have been described.7 The
two phases described in patients with FIRES suggest a possible
infection-triggered process rather than an infectious entity. Thus,
since most of the patients had seizures immediately following a
febrile episode, an autoimmune mechanism could be considered.
In the literature, the association of epilepsy and an autoimmune
process has been reported in neurologic diseases.15–22 Different
antibodies have been investigated in patients with FIRES with
negative results.3,16–22 Nevertheless, studies in patients with a
similar entity positive antibodies, such as anti-GAD antibodies,
anti-GluR3 antibodies, and antibodies against GluRepsilon 2,have been detected.6,9 These autoantibodies have previously
been found in patients with epilepsy, but not speciﬁcally in cases
with FIRES. It has been postulated that these ﬁndings may
represent a secondary phenomenon rather than the primary
pathogenic mechanism.20 Although an autoimmune mechanism
may be the main pathogenic process in a subgroup of these
patients, up to now there no evidence to support that
autoantibodies are the etiology of FIRES.
Environmental factors, such as fever or an unidentiﬁed
infectious agent may also trigger the clinical expression of the
underlying epileptic predisposition. A similar phenomenon has
been shown in, for example, Dravet syndrome and migrating
focal seizures in infancy.13,23–26 A FIRES-like syndrome associat-
ed with refractory status epilepticus may be due to PCDH19
mutations in girls.27 These ﬁndings may lead us to investigate a
genetic origin in patients with FIRES. Considering the good
response to the ketogenic diet, some patients with FIRES may be
considered to have another clinical phenotype of a glucose
transporter defect.14
Prospective, collaborative, and multicenter studies in patients
with electroclinical features compatible with FIRES would be
necessary to further investigate the probable etiology, pathogene-
sis, treatment, and outcome, and to deﬁne its nosological place.
Furthermore, it would be important to create an international
consensus group to deﬁne a treatment protocol to improve the
management of patients with this severe entity.
5. Conclusion
FIRES is a well-deﬁned severe epileptic syndrome, probably in
the group of epileptic encephalopathies, characterized by focal or
multifocal seizures arising from the neocortical regions with an as
yet unknown etiology.
The course of our series of patients was generally severe, with
seizures refractory to different therapeutic options, and associated
with mental retardation and behavioral disturbances. Two of them
had a good outcome.
In the acute phase, the status epilepticus was stopped with high
doses of barbiturates in ﬁve patients. The ketogenic diet was useful
in two patients, one of whom maintained a good response, and
another patient responded well to IVIG. In the chronic phase, IVIG,
the ketogenic diet, and surgery may be considered.
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